Drug delivery development deal for Bespak:
This article was originally published in Clinica
The developer of drug delivery technologies, Bespak (Milton Keynes), has agreed to collaborate with fellow UK company, Innovata Biomed (IB), the respiratory division of ML Laboratories, on the development of IB's C200 multi-dose dry powder inhaler device, used to deliver combination drug therapies for diseases such as asthma. Bespak will manufacture the devices on a pilot scale as required for the clinical trial of the therapy. According to ML Laboratories, IB has already found a European distributor - whose name was not disclosed - for the C200 inhaler, following "a multi-million pound licensing agreement".